nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Temsirolimus—kidney cancer	0.0646	0.0928	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0646	0.0928	CbGbCtD
Ondansetron—CYP3A5—Temsirolimus—kidney cancer	0.0485	0.0696	CbGbCtD
Ondansetron—KCNH2—Sunitinib—kidney cancer	0.0312	0.0448	CbGbCtD
Ondansetron—CYP2D6—Temsirolimus—kidney cancer	0.0297	0.0427	CbGbCtD
Ondansetron—CYP3A4—Everolimus—kidney cancer	0.028	0.0402	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0222	0.0318	CbGbCtD
Ondansetron—CYP3A7—Paclitaxel—kidney cancer	0.0222	0.0318	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0197	0.0283	CbGbCtD
Ondansetron—CYP3A7—Sorafenib—kidney cancer	0.0197	0.0283	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0191	0.0274	CbGbCtD
Ondansetron—CYP3A7—Vincristine—kidney cancer	0.0191	0.0274	CbGbCtD
Ondansetron—CYP1A2—Pazopanib—kidney cancer	0.019	0.0272	CbGbCtD
Ondansetron—CYP3A4—Temsirolimus—kidney cancer	0.0189	0.0271	CbGbCtD
Ondansetron—CYP3A5—Erlotinib—kidney cancer	0.0182	0.0261	CbGbCtD
Ondansetron—CYP2C9—Capecitabine—kidney cancer	0.0178	0.0256	CbGbCtD
Ondansetron—CYP3A5—Paclitaxel—kidney cancer	0.0166	0.0239	CbGbCtD
Ondansetron—CYP3A7—Sunitinib—kidney cancer	0.016	0.0229	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.016	0.0229	CbGbCtD
Ondansetron—CYP2D6—Pazopanib—kidney cancer	0.0156	0.0224	CbGbCtD
Ondansetron—CYP3A5—Sorafenib—kidney cancer	0.0148	0.0212	CbGbCtD
Ondansetron—CYP3A5—Vincristine—kidney cancer	0.0143	0.0206	CbGbCtD
Ondansetron—CYP1A2—Erlotinib—kidney cancer	0.0135	0.0194	CbGbCtD
Ondansetron—CYP3A5—Sunitinib—kidney cancer	0.012	0.0172	CbGbCtD
Ondansetron—CYP2C9—Paclitaxel—kidney cancer	0.0112	0.016	CbGbCtD
Ondansetron—CYP2D6—Erlotinib—kidney cancer	0.0111	0.016	CbGbCtD
Ondansetron—CYP1A2—Sorafenib—kidney cancer	0.011	0.0158	CbGbCtD
Ondansetron—CYP3A4—Pazopanib—kidney cancer	0.00993	0.0143	CbGbCtD
Ondansetron—CYP2C9—Sorafenib—kidney cancer	0.00991	0.0142	CbGbCtD
Ondansetron—CYP2D6—Sorafenib—kidney cancer	0.00906	0.013	CbGbCtD
Ondansetron—CYP2D6—Vinblastine—kidney cancer	0.00895	0.0128	CbGbCtD
Ondansetron—CYP3A4—Erlotinib—kidney cancer	0.00709	0.0102	CbGbCtD
Ondansetron—CYP3A4—Paclitaxel—kidney cancer	0.00649	0.00931	CbGbCtD
Ondansetron—CYP3A4—Sorafenib—kidney cancer	0.00576	0.00827	CbGbCtD
Ondansetron—CYP3A4—Vinblastine—kidney cancer	0.00569	0.00817	CbGbCtD
Ondansetron—CYP3A4—Vincristine—kidney cancer	0.00559	0.00803	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—kidney cancer	0.0055	0.00789	CbGbCtD
Ondansetron—CYP3A4—Sunitinib—kidney cancer	0.00467	0.0067	CbGbCtD
Ondansetron—SLC47A2—renal system—kidney cancer	0.00362	0.0874	CbGeAlD
Ondansetron—CYP3A4—Doxorubicin—kidney cancer	0.0035	0.00502	CbGbCtD
Ondansetron—SLC47A2—kidney—kidney cancer	0.0035	0.0845	CbGeAlD
Ondansetron—SLC47A2—cortex of kidney—kidney cancer	0.0034	0.0823	CbGeAlD
Ondansetron—CYP1A2—urine—kidney cancer	0.00272	0.0656	CbGeAlD
Ondansetron—CYP2C9—urine—kidney cancer	0.00258	0.0623	CbGeAlD
Ondansetron—CYP2E1—urine—kidney cancer	0.00244	0.0591	CbGeAlD
Ondansetron—CYP3A4—urine—kidney cancer	0.00197	0.0475	CbGeAlD
Ondansetron—CYP2D6—urine—kidney cancer	0.00193	0.0468	CbGeAlD
Ondansetron—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.0017	0.0412	CbGeAlD
Ondansetron—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00146	0.0352	CbGeAlD
Ondansetron—SLC47A1—nephron tubule—kidney cancer	0.00139	0.0336	CbGeAlD
Ondansetron—SLC47A1—renal system—kidney cancer	0.00127	0.0306	CbGeAlD
Ondansetron—SLC47A1—kidney—kidney cancer	0.00122	0.0296	CbGeAlD
Ondansetron—SLC47A1—cortex of kidney—kidney cancer	0.00119	0.0288	CbGeAlD
Ondansetron—SLC47A1—gonad—kidney cancer	0.00113	0.0274	CbGeAlD
Ondansetron—HTR1A—renal system—kidney cancer	0.000872	0.0211	CbGeAlD
Ondansetron—KCNH2—renal system—kidney cancer	0.000776	0.0188	CbGeAlD
Ondansetron—CYP3A5—nephron tubule—kidney cancer	0.000705	0.017	CbGeAlD
Ondansetron—KCNH2—cardiac atrium—kidney cancer	0.000695	0.0168	CbGeAlD
Ondansetron—CYP1A2—renal system—kidney cancer	0.000665	0.0161	CbGeAlD
Ondansetron—CYP2E1—nephron tubule—kidney cancer	0.000658	0.0159	CbGeAlD
Ondansetron—CYP3A5—renal system—kidney cancer	0.000641	0.0155	CbGeAlD
Ondansetron—CYP3A5—kidney—kidney cancer	0.00062	0.015	CbGeAlD
Ondansetron—CYP3A5—cortex of kidney—kidney cancer	0.000604	0.0146	CbGeAlD
Ondansetron—CYP2E1—renal system—kidney cancer	0.000598	0.0144	CbGeAlD
Ondansetron—CYP2E1—kidney—kidney cancer	0.000578	0.014	CbGeAlD
Ondansetron—CYP2E1—cortex of kidney—kidney cancer	0.000563	0.0136	CbGeAlD
Ondansetron—CYP3A4—renal system—kidney cancer	0.000481	0.0116	CbGeAlD
Ondansetron—CYP2D6—renal system—kidney cancer	0.000473	0.0114	CbGeAlD
Ondansetron—CYP3A4—kidney—kidney cancer	0.000465	0.0112	CbGeAlD
Ondansetron—CYP2D6—kidney—kidney cancer	0.000458	0.0111	CbGeAlD
Ondansetron—Hepatobiliary disease—Capecitabine—kidney cancer	0.000189	0.000895	CcSEcCtD
Ondansetron—Pruritus—Erlotinib—kidney cancer	0.000189	0.000895	CcSEcCtD
Ondansetron—Fatigue—Dactinomycin—kidney cancer	0.000188	0.000894	CcSEcCtD
Ondansetron—Flatulence—Paclitaxel—kidney cancer	0.000187	0.000888	CcSEcCtD
Ondansetron—Pain—Dactinomycin—kidney cancer	0.000187	0.000887	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—kidney cancer	0.000186	0.000881	CcSEcCtD
Ondansetron—Anaphylactic shock—Gemcitabine—kidney cancer	0.000185	0.000879	CcSEcCtD
Ondansetron—Dizziness—Vinblastine—kidney cancer	0.000183	0.00087	CcSEcCtD
Ondansetron—Dizziness—Everolimus—kidney cancer	0.000183	0.000867	CcSEcCtD
Ondansetron—Abdominal pain—Sunitinib—kidney cancer	0.000182	0.000866	CcSEcCtD
Ondansetron—Body temperature increased—Sunitinib—kidney cancer	0.000182	0.000866	CcSEcCtD
Ondansetron—Diarrhoea—Erlotinib—kidney cancer	0.000182	0.000866	CcSEcCtD
Ondansetron—Hypotension—Vincristine—kidney cancer	0.000182	0.000866	CcSEcCtD
Ondansetron—Bradycardia—Capecitabine—kidney cancer	0.000182	0.000865	CcSEcCtD
Ondansetron—Nervous system disorder—Gemcitabine—kidney cancer	0.000182	0.000862	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—kidney cancer	0.00018	0.000854	CcSEcCtD
Ondansetron—Haemoglobin—Capecitabine—kidney cancer	0.00018	0.000854	CcSEcCtD
Ondansetron—Skin disorder—Gemcitabine—kidney cancer	0.00018	0.000854	CcSEcCtD
Ondansetron—Haemorrhage—Capecitabine—kidney cancer	0.000179	0.00085	CcSEcCtD
Ondansetron—Vision blurred—Paclitaxel—kidney cancer	0.000179	0.00085	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000179	0.000848	CcSEcCtD
Ondansetron—Tremor—Paclitaxel—kidney cancer	0.000178	0.000845	CcSEcCtD
Ondansetron—Hypersensitivity—Sorafenib—kidney cancer	0.000177	0.000839	CcSEcCtD
Ondansetron—Vomiting—Vinblastine—kidney cancer	0.000176	0.000837	CcSEcCtD
Ondansetron—Dizziness—Erlotinib—kidney cancer	0.000176	0.000837	CcSEcCtD
Ondansetron—Ill-defined disorder—Paclitaxel—kidney cancer	0.000176	0.000836	CcSEcCtD
Ondansetron—Vomiting—Everolimus—kidney cancer	0.000176	0.000834	CcSEcCtD
Ondansetron—Paraesthesia—Vincristine—kidney cancer	0.000175	0.000832	CcSEcCtD
Ondansetron—Agitation—Paclitaxel—kidney cancer	0.000175	0.000828	CcSEcCtD
Ondansetron—Rash—Everolimus—kidney cancer	0.000174	0.000827	CcSEcCtD
Ondansetron—Dermatitis—Everolimus—kidney cancer	0.000174	0.000826	CcSEcCtD
Ondansetron—Headache—Vinblastine—kidney cancer	0.000174	0.000825	CcSEcCtD
Ondansetron—Angioedema—Paclitaxel—kidney cancer	0.000174	0.000824	CcSEcCtD
Ondansetron—Headache—Everolimus—kidney cancer	0.000173	0.000821	CcSEcCtD
Ondansetron—Hypotension—Gemcitabine—kidney cancer	0.000173	0.000821	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—kidney cancer	0.000173	0.00082	CcSEcCtD
Ondansetron—Abdominal pain—Dactinomycin—kidney cancer	0.000173	0.00082	CcSEcCtD
Ondansetron—Visual impairment—Capecitabine—kidney cancer	0.000173	0.000819	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000172	0.000818	CcSEcCtD
Ondansetron—Asthenia—Sorafenib—kidney cancer	0.000172	0.000817	CcSEcCtD
Ondansetron—Malaise—Paclitaxel—kidney cancer	0.000171	0.000813	CcSEcCtD
Ondansetron—Syncope—Paclitaxel—kidney cancer	0.00017	0.000808	CcSEcCtD
Ondansetron—Hypersensitivity—Sunitinib—kidney cancer	0.00017	0.000807	CcSEcCtD
Ondansetron—Pruritus—Sorafenib—kidney cancer	0.00017	0.000805	CcSEcCtD
Ondansetron—Vomiting—Erlotinib—kidney cancer	0.00017	0.000804	CcSEcCtD
Ondansetron—Erythema multiforme—Capecitabine—kidney cancer	0.000169	0.000804	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vincristine—kidney cancer	0.000169	0.0008	CcSEcCtD
Ondansetron—Fatigue—Vincristine—kidney cancer	0.000168	0.000799	CcSEcCtD
Ondansetron—Rash—Erlotinib—kidney cancer	0.000168	0.000798	CcSEcCtD
Ondansetron—Dermatitis—Erlotinib—kidney cancer	0.000168	0.000797	CcSEcCtD
Ondansetron—Palpitations—Paclitaxel—kidney cancer	0.000168	0.000797	CcSEcCtD
Ondansetron—Eye disorder—Capecitabine—kidney cancer	0.000167	0.000794	CcSEcCtD
Ondansetron—Headache—Erlotinib—kidney cancer	0.000167	0.000793	CcSEcCtD
Ondansetron—Loss of consciousness—Paclitaxel—kidney cancer	0.000167	0.000792	CcSEcCtD
Ondansetron—Pain—Vincristine—kidney cancer	0.000167	0.000792	CcSEcCtD
Ondansetron—Constipation—Vincristine—kidney cancer	0.000167	0.000792	CcSEcCtD
Ondansetron—Paraesthesia—Gemcitabine—kidney cancer	0.000166	0.000789	CcSEcCtD
Ondansetron—Flushing—Capecitabine—kidney cancer	0.000166	0.000789	CcSEcCtD
Ondansetron—Cardiac disorder—Capecitabine—kidney cancer	0.000166	0.000789	CcSEcCtD
Ondansetron—Cough—Paclitaxel—kidney cancer	0.000166	0.000787	CcSEcCtD
Ondansetron—Asthenia—Sunitinib—kidney cancer	0.000166	0.000786	CcSEcCtD
Ondansetron—Dyspnoea—Gemcitabine—kidney cancer	0.000165	0.000783	CcSEcCtD
Ondansetron—Somnolence—Gemcitabine—kidney cancer	0.000165	0.000781	CcSEcCtD
Ondansetron—Convulsion—Paclitaxel—kidney cancer	0.000165	0.000781	CcSEcCtD
Ondansetron—Diarrhoea—Sorafenib—kidney cancer	0.000164	0.000779	CcSEcCtD
Ondansetron—Pruritus—Sunitinib—kidney cancer	0.000163	0.000775	CcSEcCtD
Ondansetron—Angiopathy—Capecitabine—kidney cancer	0.000163	0.000771	CcSEcCtD
Ondansetron—Immune system disorder—Capecitabine—kidney cancer	0.000162	0.000768	CcSEcCtD
Ondansetron—Chest pain—Paclitaxel—kidney cancer	0.000162	0.000768	CcSEcCtD
Ondansetron—Mediastinal disorder—Capecitabine—kidney cancer	0.000161	0.000766	CcSEcCtD
Ondansetron—Anxiety—Paclitaxel—kidney cancer	0.000161	0.000765	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—kidney cancer	0.000161	0.000764	CcSEcCtD
Ondansetron—Chills—Capecitabine—kidney cancer	0.000161	0.000763	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000161	0.000762	CcSEcCtD
Ondansetron—Arrhythmia—Capecitabine—kidney cancer	0.00016	0.000759	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00016	0.000759	CcSEcCtD
Ondansetron—Discomfort—Paclitaxel—kidney cancer	0.00016	0.000758	CcSEcCtD
Ondansetron—Fatigue—Gemcitabine—kidney cancer	0.00016	0.000758	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vincristine—kidney cancer	0.00016	0.000758	CcSEcCtD
Ondansetron—Dizziness—Sorafenib—kidney cancer	0.000159	0.000753	CcSEcCtD
Ondansetron—Pain—Gemcitabine—kidney cancer	0.000158	0.000751	CcSEcCtD
Ondansetron—Constipation—Gemcitabine—kidney cancer	0.000158	0.000751	CcSEcCtD
Ondansetron—Dry mouth—Paclitaxel—kidney cancer	0.000158	0.000751	CcSEcCtD
Ondansetron—Diarrhoea—Sunitinib—kidney cancer	0.000158	0.000749	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—kidney cancer	0.000157	0.000744	CcSEcCtD
Ondansetron—Erythema—Capecitabine—kidney cancer	0.000156	0.00074	CcSEcCtD
Ondansetron—Anaphylactic shock—Paclitaxel—kidney cancer	0.000155	0.000736	CcSEcCtD
Ondansetron—Abdominal pain—Vincristine—kidney cancer	0.000154	0.000732	CcSEcCtD
Ondansetron—Body temperature increased—Vincristine—kidney cancer	0.000154	0.000732	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—kidney cancer	0.000154	0.000731	CcSEcCtD
Ondansetron—Flatulence—Capecitabine—kidney cancer	0.000154	0.000729	CcSEcCtD
Ondansetron—Dizziness—Sunitinib—kidney cancer	0.000153	0.000724	CcSEcCtD
Ondansetron—Feeling abnormal—Gemcitabine—kidney cancer	0.000153	0.000724	CcSEcCtD
Ondansetron—Shock—Paclitaxel—kidney cancer	0.000153	0.000724	CcSEcCtD
Ondansetron—Vomiting—Sorafenib—kidney cancer	0.000153	0.000724	CcSEcCtD
Ondansetron—Nervous system disorder—Paclitaxel—kidney cancer	0.000152	0.000722	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—kidney cancer	0.000152	0.000721	CcSEcCtD
Ondansetron—Tachycardia—Paclitaxel—kidney cancer	0.000151	0.000718	CcSEcCtD
Ondansetron—Rash—Sorafenib—kidney cancer	0.000151	0.000718	CcSEcCtD
Ondansetron—Dermatitis—Sorafenib—kidney cancer	0.000151	0.000717	CcSEcCtD
Ondansetron—Skin disorder—Paclitaxel—kidney cancer	0.000151	0.000715	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.00015	0.000713	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.00015	0.000713	CcSEcCtD
Ondansetron—Headache—Sorafenib—kidney cancer	0.00015	0.000713	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—kidney cancer	0.00015	0.000709	CcSEcCtD
Ondansetron—Vision blurred—Capecitabine—kidney cancer	0.000147	0.000697	CcSEcCtD
Ondansetron—Vomiting—Sunitinib—kidney cancer	0.000147	0.000696	CcSEcCtD
Ondansetron—Body temperature increased—Gemcitabine—kidney cancer	0.000146	0.000695	CcSEcCtD
Ondansetron—Tremor—Capecitabine—kidney cancer	0.000146	0.000693	CcSEcCtD
Ondansetron—Rash—Sunitinib—kidney cancer	0.000146	0.000691	CcSEcCtD
Ondansetron—Dermatitis—Sunitinib—kidney cancer	0.000145	0.00069	CcSEcCtD
Ondansetron—Hypotension—Paclitaxel—kidney cancer	0.000145	0.000688	CcSEcCtD
Ondansetron—Ill-defined disorder—Capecitabine—kidney cancer	0.000145	0.000686	CcSEcCtD
Ondansetron—Headache—Sunitinib—kidney cancer	0.000145	0.000686	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—kidney cancer	0.000144	0.000684	CcSEcCtD
Ondansetron—Hypersensitivity—Vincristine—kidney cancer	0.000144	0.000683	CcSEcCtD
Ondansetron—Malaise—Capecitabine—kidney cancer	0.000141	0.000667	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—kidney cancer	0.000141	0.000667	CcSEcCtD
Ondansetron—Asthenia—Vincristine—kidney cancer	0.00014	0.000665	CcSEcCtD
Ondansetron—Syncope—Capecitabine—kidney cancer	0.00014	0.000663	CcSEcCtD
Ondansetron—Paraesthesia—Paclitaxel—kidney cancer	0.000139	0.000661	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—kidney cancer	0.000139	0.000659	CcSEcCtD
Ondansetron—Dyspnoea—Paclitaxel—kidney cancer	0.000138	0.000656	CcSEcCtD
Ondansetron—Somnolence—Paclitaxel—kidney cancer	0.000138	0.000654	CcSEcCtD
Ondansetron—Palpitations—Capecitabine—kidney cancer	0.000138	0.000654	CcSEcCtD
Ondansetron—Rash—Dactinomycin—kidney cancer	0.000138	0.000654	CcSEcCtD
Ondansetron—Loss of consciousness—Capecitabine—kidney cancer	0.000137	0.00065	CcSEcCtD
Ondansetron—Cough—Capecitabine—kidney cancer	0.000136	0.000646	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—kidney cancer	0.000135	0.00064	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000134	0.000635	CcSEcCtD
Ondansetron—Fatigue—Paclitaxel—kidney cancer	0.000134	0.000634	CcSEcCtD
Ondansetron—Diarrhoea—Vincristine—kidney cancer	0.000134	0.000634	CcSEcCtD
Ondansetron—Asthenia—Gemcitabine—kidney cancer	0.000133	0.000631	CcSEcCtD
Ondansetron—Chest pain—Capecitabine—kidney cancer	0.000133	0.00063	CcSEcCtD
Ondansetron—Constipation—Paclitaxel—kidney cancer	0.000133	0.000629	CcSEcCtD
Ondansetron—Pain—Paclitaxel—kidney cancer	0.000133	0.000629	CcSEcCtD
Ondansetron—Anxiety—Capecitabine—kidney cancer	0.000132	0.000628	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000132	0.000626	CcSEcCtD
Ondansetron—Discomfort—Capecitabine—kidney cancer	0.000131	0.000622	CcSEcCtD
Ondansetron—Pruritus—Gemcitabine—kidney cancer	0.000131	0.000622	CcSEcCtD
Ondansetron—Dry mouth—Capecitabine—kidney cancer	0.00013	0.000616	CcSEcCtD
Ondansetron—Dizziness—Vincristine—kidney cancer	0.000129	0.000613	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—kidney cancer	0.000129	0.00061	CcSEcCtD
Ondansetron—Feeling abnormal—Paclitaxel—kidney cancer	0.000128	0.000606	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000128	0.000605	CcSEcCtD
Ondansetron—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000127	0.000602	CcSEcCtD
Ondansetron—Diarrhoea—Gemcitabine—kidney cancer	0.000127	0.000601	CcSEcCtD
Ondansetron—Shock—Capecitabine—kidney cancer	0.000125	0.000594	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—kidney cancer	0.000125	0.000593	CcSEcCtD
Ondansetron—Nervous system disorder—Capecitabine—kidney cancer	0.000125	0.000592	CcSEcCtD
Ondansetron—Tachycardia—Capecitabine—kidney cancer	0.000124	0.000589	CcSEcCtD
Ondansetron—Vomiting—Vincristine—kidney cancer	0.000124	0.000589	CcSEcCtD
Ondansetron—Skin disorder—Capecitabine—kidney cancer	0.000124	0.000586	CcSEcCtD
Ondansetron—Urticaria—Paclitaxel—kidney cancer	0.000123	0.000585	CcSEcCtD
Ondansetron—Rash—Vincristine—kidney cancer	0.000123	0.000584	CcSEcCtD
Ondansetron—Dermatitis—Vincristine—kidney cancer	0.000123	0.000584	CcSEcCtD
Ondansetron—Abdominal pain—Paclitaxel—kidney cancer	0.000123	0.000582	CcSEcCtD
Ondansetron—Body temperature increased—Paclitaxel—kidney cancer	0.000123	0.000582	CcSEcCtD
Ondansetron—Headache—Vincristine—kidney cancer	0.000122	0.00058	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000122	0.000577	CcSEcCtD
Ondansetron—Hypotension—Capecitabine—kidney cancer	0.000119	0.000564	CcSEcCtD
Ondansetron—Vomiting—Gemcitabine—kidney cancer	0.000118	0.000559	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—kidney cancer	0.000118	0.000558	CcSEcCtD
Ondansetron—Rash—Gemcitabine—kidney cancer	0.000117	0.000554	CcSEcCtD
Ondansetron—Dermatitis—Gemcitabine—kidney cancer	0.000117	0.000554	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—kidney cancer	0.000116	0.000551	CcSEcCtD
Ondansetron—Headache—Gemcitabine—kidney cancer	0.000116	0.000551	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—kidney cancer	0.000115	0.000548	CcSEcCtD
Ondansetron—Paraesthesia—Capecitabine—kidney cancer	0.000114	0.000542	CcSEcCtD
Ondansetron—Hypersensitivity—Paclitaxel—kidney cancer	0.000114	0.000542	CcSEcCtD
Ondansetron—Dyspnoea—Capecitabine—kidney cancer	0.000113	0.000538	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—kidney cancer	0.000111	0.000528	CcSEcCtD
Ondansetron—Asthenia—Paclitaxel—kidney cancer	0.000111	0.000528	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00011	0.000521	CcSEcCtD
Ondansetron—Fatigue—Capecitabine—kidney cancer	0.00011	0.000521	CcSEcCtD
Ondansetron—Pruritus—Paclitaxel—kidney cancer	0.00011	0.000521	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—kidney cancer	0.000109	0.000518	CcSEcCtD
Ondansetron—Constipation—Capecitabine—kidney cancer	0.000109	0.000516	CcSEcCtD
Ondansetron—Pain—Capecitabine—kidney cancer	0.000109	0.000516	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—kidney cancer	0.000108	0.000512	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—kidney cancer	0.000107	0.000508	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—kidney cancer	0.000107	0.000508	CcSEcCtD
Ondansetron—Diarrhoea—Paclitaxel—kidney cancer	0.000106	0.000503	CcSEcCtD
Ondansetron—Feeling abnormal—Capecitabine—kidney cancer	0.000105	0.000498	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—kidney cancer	0.000105	0.000497	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—kidney cancer	0.000104	0.000495	CcSEcCtD
Ondansetron—Gastrointestinal pain—Capecitabine—kidney cancer	0.000104	0.000494	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—kidney cancer	0.000104	0.000494	CcSEcCtD
Ondansetron—Chills—Doxorubicin—kidney cancer	0.000104	0.000492	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—kidney cancer	0.000103	0.000489	CcSEcCtD
Ondansetron—Dizziness—Paclitaxel—kidney cancer	0.000103	0.000487	CcSEcCtD
Ondansetron—Urticaria—Capecitabine—kidney cancer	0.000101	0.00048	CcSEcCtD
Ondansetron—Body temperature increased—Capecitabine—kidney cancer	0.000101	0.000477	CcSEcCtD
Ondansetron—Abdominal pain—Capecitabine—kidney cancer	0.000101	0.000477	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—kidney cancer	0.000101	0.000477	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—kidney cancer	9.9e-05	0.00047	CcSEcCtD
Ondansetron—Vomiting—Paclitaxel—kidney cancer	9.86e-05	0.000468	CcSEcCtD
Ondansetron—Rash—Paclitaxel—kidney cancer	9.78e-05	0.000464	CcSEcCtD
Ondansetron—Dermatitis—Paclitaxel—kidney cancer	9.77e-05	0.000463	CcSEcCtD
Ondansetron—Headache—Paclitaxel—kidney cancer	9.72e-05	0.000461	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—kidney cancer	9.47e-05	0.000449	CcSEcCtD
Ondansetron—Hypersensitivity—Capecitabine—kidney cancer	9.38e-05	0.000445	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—kidney cancer	9.33e-05	0.000442	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—kidney cancer	9.24e-05	0.000438	CcSEcCtD
Ondansetron—Asthenia—Capecitabine—kidney cancer	9.13e-05	0.000433	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—kidney cancer	9.06e-05	0.00043	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—kidney cancer	9.01e-05	0.000428	CcSEcCtD
Ondansetron—Pruritus—Capecitabine—kidney cancer	9e-05	0.000427	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—kidney cancer	8.88e-05	0.000421	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—kidney cancer	8.83e-05	0.000419	CcSEcCtD
Ondansetron—Cough—Doxorubicin—kidney cancer	8.77e-05	0.000416	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—kidney cancer	8.71e-05	0.000413	CcSEcCtD
Ondansetron—Diarrhoea—Capecitabine—kidney cancer	8.71e-05	0.000413	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—kidney cancer	8.56e-05	0.000406	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—kidney cancer	8.53e-05	0.000405	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	8.5e-05	0.000403	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—kidney cancer	8.45e-05	0.000401	CcSEcCtD
Ondansetron—Dizziness—Capecitabine—kidney cancer	8.42e-05	0.000399	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—kidney cancer	8.37e-05	0.000397	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—kidney cancer	8.2e-05	0.000389	CcSEcCtD
Ondansetron—Vomiting—Capecitabine—kidney cancer	8.09e-05	0.000384	CcSEcCtD
Ondansetron—Shock—Doxorubicin—kidney cancer	8.07e-05	0.000383	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—kidney cancer	8.05e-05	0.000382	CcSEcCtD
Ondansetron—Rash—Capecitabine—kidney cancer	8.02e-05	0.000381	CcSEcCtD
Ondansetron—Dermatitis—Capecitabine—kidney cancer	8.02e-05	0.00038	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—kidney cancer	8.01e-05	0.00038	CcSEcCtD
Ondansetron—Headache—Capecitabine—kidney cancer	7.97e-05	0.000378	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—kidney cancer	7.97e-05	0.000378	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—kidney cancer	7.67e-05	0.000364	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—kidney cancer	7.37e-05	0.000349	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—kidney cancer	7.31e-05	0.000347	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—kidney cancer	7.29e-05	0.000346	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.08e-05	0.000336	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—kidney cancer	7.07e-05	0.000336	CcSEcCtD
Ondansetron—Pain—Doxorubicin—kidney cancer	7.02e-05	0.000333	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—kidney cancer	7.02e-05	0.000333	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—kidney cancer	6.76e-05	0.000321	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—kidney cancer	6.71e-05	0.000318	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—kidney cancer	6.52e-05	0.000309	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—kidney cancer	6.49e-05	0.000308	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—kidney cancer	6.49e-05	0.000308	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—kidney cancer	6.04e-05	0.000287	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—kidney cancer	5.89e-05	0.000279	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—kidney cancer	5.8e-05	0.000275	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—kidney cancer	5.61e-05	0.000266	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—kidney cancer	5.42e-05	0.000257	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—kidney cancer	5.22e-05	0.000247	CcSEcCtD
Ondansetron—Rash—Doxorubicin—kidney cancer	5.17e-05	0.000245	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—kidney cancer	5.17e-05	0.000245	CcSEcCtD
Ondansetron—Headache—Doxorubicin—kidney cancer	5.14e-05	0.000244	CcSEcCtD
Ondansetron—CYP3A5—Metabolism—ACHE—kidney cancer	1.09e-05	0.000213	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTT1—kidney cancer	1.09e-05	0.000213	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1R—kidney cancer	1.09e-05	0.000212	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CA9—kidney cancer	1.08e-05	0.000211	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.07e-05	0.00021	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PGK1—kidney cancer	1.07e-05	0.00021	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CA9—kidney cancer	1.07e-05	0.000209	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MAPK3—kidney cancer	1.07e-05	0.000208	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—POMC—kidney cancer	1.07e-05	0.000208	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—LDHB—kidney cancer	1.05e-05	0.000206	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTP1—kidney cancer	1.05e-05	0.000205	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PAK1—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUNB—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—RAF1—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MYC—kidney cancer	1.04e-05	0.000203	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SCARB1—kidney cancer	1.04e-05	0.000202	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SCARB1—kidney cancer	1.04e-05	0.000202	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—IL2—kidney cancer	1.03e-05	0.000202	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS1—kidney cancer	1.03e-05	0.0002	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS1—kidney cancer	1.02e-05	0.0002	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APRT—kidney cancer	1.02e-05	0.000199	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—FH—kidney cancer	1.02e-05	0.000199	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MAPK1—kidney cancer	1.02e-05	0.000198	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PSMD7—kidney cancer	1.01e-05	0.000197	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PSMD7—kidney cancer	1e-05	0.000196	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ABCB1—kidney cancer	9.93e-06	0.000194	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF2—kidney cancer	9.92e-06	0.000194	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN2B—kidney cancer	9.88e-06	0.000193	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—POMC—kidney cancer	9.67e-06	0.000189	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTM1—kidney cancer	9.64e-06	0.000188	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KRAS—kidney cancer	9.59e-06	0.000187	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1R—kidney cancer	9.59e-06	0.000187	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPC3—kidney cancer	9.57e-06	0.000187	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—BCHE—kidney cancer	9.55e-06	0.000186	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—BCHE—kidney cancer	9.53e-06	0.000186	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SLC5A5—kidney cancer	9.43e-06	0.000184	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SLC5A5—kidney cancer	9.41e-06	0.000184	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL2—kidney cancer	9.39e-06	0.000183	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CA2—kidney cancer	9.31e-06	0.000182	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—RAF1—kidney cancer	9.24e-06	0.00018	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CRABP1—kidney cancer	9.17e-06	0.000179	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CA9—kidney cancer	9.14e-06	0.000178	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP1A1—kidney cancer	9.13e-06	0.000178	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL2—kidney cancer	9.12e-06	0.000178	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SLC2A1—kidney cancer	9.11e-06	0.000178	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CRABP1—kidney cancer	9.09e-06	0.000177	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SLC2A1—kidney cancer	9.09e-06	0.000177	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALAD—kidney cancer	9.07e-06	0.000177	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HIF1A—kidney cancer	8.95e-06	0.000175	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.93e-06	0.000174	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TSC2—kidney cancer	8.92e-06	0.000174	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ST3GAL2—kidney cancer	8.85e-06	0.000173	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PIK3CA—kidney cancer	8.81e-06	0.000172	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALDH1A1—kidney cancer	8.65e-06	0.000169	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF2—kidney cancer	8.56e-06	0.000167	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KDR—kidney cancer	8.56e-06	0.000167	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ITPR2—kidney cancer	8.53e-06	0.000166	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN2B—kidney cancer	8.52e-06	0.000166	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—kidney cancer	8.52e-06	0.000166	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ITPR2—kidney cancer	8.45e-06	0.000165	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PGK1—kidney cancer	8.29e-06	0.000162	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A3—kidney cancer	8.29e-06	0.000162	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL2—kidney cancer	8.29e-06	0.000162	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1R—kidney cancer	8.28e-06	0.000162	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LDHB—kidney cancer	8.13e-06	0.000159	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—RAF1—kidney cancer	7.98e-06	0.000156	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HIF1A—kidney cancer	7.9e-06	0.000154	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—APC—kidney cancer	7.88e-06	0.000154	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KIT—kidney cancer	7.88e-06	0.000154	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—kidney cancer	7.88e-06	0.000154	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TSC2—kidney cancer	7.88e-06	0.000154	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.79e-06	0.000152	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTT1—kidney cancer	7.78e-06	0.000152	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ACHE—kidney cancer	7.78e-06	0.000152	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CRABP1—kidney cancer	7.77e-06	0.000152	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ACHE—kidney cancer	7.71e-06	0.00015	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTT1—kidney cancer	7.71e-06	0.00015	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—kidney cancer	7.59e-06	0.000148	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—kidney cancer	7.58e-06	0.000148	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KDR—kidney cancer	7.55e-06	0.000147	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK3—kidney cancer	7.55e-06	0.000147	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—POMC—kidney cancer	7.5e-06	0.000146	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—BRAF—kidney cancer	7.41e-06	0.000145	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SCARB1—kidney cancer	7.36e-06	0.000144	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SCARB1—kidney cancer	7.3e-06	0.000142	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS1—kidney cancer	7.29e-06	0.000142	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ITPR2—kidney cancer	7.22e-06	0.000141	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS1—kidney cancer	7.22e-06	0.000141	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ABCB1—kidney cancer	7.19e-06	0.00014	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK1—kidney cancer	7.18e-06	0.00014	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ABCB1—kidney cancer	7.17e-06	0.00014	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—kidney cancer	7.15e-06	0.00014	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PSMD7—kidney cancer	7.15e-06	0.000139	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PSMD7—kidney cancer	7.08e-06	0.000138	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CA9—kidney cancer	7.05e-06	0.000138	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—kidney cancer	6.98e-06	0.000136	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—kidney cancer	6.96e-06	0.000136	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KIT—kidney cancer	6.96e-06	0.000136	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APC—kidney cancer	6.96e-06	0.000136	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—kidney cancer	6.86e-06	0.000134	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HIF1A—kidney cancer	6.82e-06	0.000133	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—POMC—kidney cancer	6.81e-06	0.000133	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TSC2—kidney cancer	6.8e-06	0.000133	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—kidney cancer	6.78e-06	0.000132	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—BCHE—kidney cancer	6.77e-06	0.000132	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—BCHE—kidney cancer	6.71e-06	0.000131	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC5A5—kidney cancer	6.69e-06	0.000131	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK3—kidney cancer	6.66e-06	0.00013	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.66e-06	0.00013	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC5A5—kidney cancer	6.63e-06	0.000129	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—POMC—kidney cancer	6.62e-06	0.000129	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1A1—kidney cancer	6.62e-06	0.000129	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1A1—kidney cancer	6.6e-06	0.000129	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTT1—kidney cancer	6.59e-06	0.000129	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ACHE—kidney cancer	6.59e-06	0.000129	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—BRAF—kidney cancer	6.54e-06	0.000128	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KDR—kidney cancer	6.52e-06	0.000127	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A1—kidney cancer	6.46e-06	0.000126	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A1—kidney cancer	6.41e-06	0.000125	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK1—kidney cancer	6.34e-06	0.000124	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SCARB1—kidney cancer	6.24e-06	0.000122	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—kidney cancer	6.23e-06	0.000122	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.22e-06	0.000121	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RAF1—kidney cancer	6.19e-06	0.000121	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS1—kidney cancer	6.17e-06	0.00012	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RELA—kidney cancer	6.16e-06	0.00012	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—kidney cancer	6.12e-06	0.000119	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—kidney cancer	6.06e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PSMD7—kidney cancer	6.05e-06	0.000118	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MTOR—kidney cancer	6.04e-06	0.000118	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APC—kidney cancer	6e-06	0.000117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KIT—kidney cancer	6e-06	0.000117	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CRABP1—kidney cancer	6e-06	0.000117	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—kidney cancer	5.99e-06	0.000117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—kidney cancer	5.75e-06	0.000112	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—BCHE—kidney cancer	5.74e-06	0.000112	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—POMC—kidney cancer	5.72e-06	0.000112	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC5A5—kidney cancer	5.67e-06	0.000111	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—kidney cancer	5.67e-06	0.000111	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—kidney cancer	5.64e-06	0.00011	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ITPR2—kidney cancer	5.57e-06	0.000109	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—kidney cancer	5.55e-06	0.000108	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—kidney cancer	5.5e-06	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A1—kidney cancer	5.47e-06	0.000107	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK1—kidney cancer	5.47e-06	0.000107	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAF1—kidney cancer	5.46e-06	0.000107	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RELA—kidney cancer	5.44e-06	0.000106	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—kidney cancer	5.43e-06	0.000106	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.42e-06	0.000106	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—kidney cancer	5.41e-06	0.000106	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—kidney cancer	5.4e-06	0.000105	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—kidney cancer	5.4e-06	0.000105	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—kidney cancer	5.39e-06	0.000105	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—kidney cancer	5.35e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—kidney cancer	5.34e-06	0.000104	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MTOR—kidney cancer	5.33e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.31e-06	0.000104	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	5.23e-06	0.000102	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—kidney cancer	5.22e-06	0.000102	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—kidney cancer	5.17e-06	0.000101	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—kidney cancer	5.1e-06	9.96e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ACHE—kidney cancer	5.08e-06	9.92e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTT1—kidney cancer	5.08e-06	9.92e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—kidney cancer	5.06e-06	9.87e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	5e-06	9.76e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—kidney cancer	4.95e-06	9.67e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—POMC—kidney cancer	4.93e-06	9.63e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—POMC—kidney cancer	4.92e-06	9.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—kidney cancer	4.91e-06	9.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—kidney cancer	4.89e-06	9.55e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SCARB1—kidney cancer	4.81e-06	9.39e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—kidney cancer	4.77e-06	9.31e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS1—kidney cancer	4.76e-06	9.3e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—kidney cancer	4.76e-06	9.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	4.75e-06	9.27e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—kidney cancer	4.74e-06	9.25e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	4.73e-06	9.22e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—kidney cancer	4.71e-06	9.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAF1—kidney cancer	4.71e-06	9.2e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A1—kidney cancer	4.7e-06	9.16e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RELA—kidney cancer	4.69e-06	9.16e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PSMD7—kidney cancer	4.67e-06	9.12e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—kidney cancer	4.66e-06	9.1e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A1—kidney cancer	4.65e-06	9.08e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.63e-06	9.04e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—kidney cancer	4.61e-06	8.99e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MTOR—kidney cancer	4.6e-06	8.98e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—kidney cancer	4.57e-06	8.91e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—kidney cancer	4.46e-06	8.7e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—BCHE—kidney cancer	4.43e-06	8.64e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.37e-06	8.54e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—kidney cancer	4.34e-06	8.46e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—kidney cancer	4.32e-06	8.43e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	4.32e-06	8.43e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK1—kidney cancer	4.24e-06	8.28e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—kidney cancer	4.23e-06	8.25e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.22e-06	8.25e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—kidney cancer	4.2e-06	8.19e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—kidney cancer	4.16e-06	8.12e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—kidney cancer	4.12e-06	8.04e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—kidney cancer	4.11e-06	8.02e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	4.08e-06	7.96e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—kidney cancer	4.01e-06	7.82e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.98e-06	7.76e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—kidney cancer	3.98e-06	7.76e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—kidney cancer	3.94e-06	7.68e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—kidney cancer	3.93e-06	7.68e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—kidney cancer	3.93e-06	7.66e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—kidney cancer	3.83e-06	7.47e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.82e-06	7.46e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK1—kidney cancer	3.74e-06	7.31e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	3.68e-06	7.19e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—kidney cancer	3.59e-06	7.01e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—kidney cancer	3.56e-06	6.95e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—kidney cancer	3.54e-06	6.9e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—kidney cancer	3.52e-06	6.88e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—POMC—kidney cancer	3.5e-06	6.83e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—POMC—kidney cancer	3.47e-06	6.77e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—kidney cancer	3.43e-06	6.7e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—kidney cancer	3.42e-06	6.68e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—kidney cancer	3.4e-06	6.63e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—kidney cancer	3.34e-06	6.52e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—kidney cancer	3.34e-06	6.51e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—kidney cancer	3.3e-06	6.45e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.27e-06	6.38e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	3.25e-06	6.34e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—kidney cancer	3.24e-06	6.32e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK1—kidney cancer	3.23e-06	6.31e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—kidney cancer	3.14e-06	6.13e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.07e-06	5.99e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—kidney cancer	3.05e-06	5.96e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—POMC—kidney cancer	2.97e-06	5.79e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	2.8e-06	5.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—kidney cancer	2.79e-06	5.45e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—kidney cancer	2.77e-06	5.4e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—kidney cancer	2.71e-06	5.3e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—kidney cancer	2.43e-06	4.75e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—kidney cancer	2.42e-06	4.72e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.42e-06	4.71e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—kidney cancer	2.41e-06	4.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—kidney cancer	2.37e-06	4.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—POMC—kidney cancer	2.29e-06	4.47e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—kidney cancer	2.06e-06	4.03e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—kidney cancer	1.83e-06	3.56e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.72e-06	3.35e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.7e-06	3.32e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—kidney cancer	1.59e-06	3.11e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.46e-06	2.84e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.12e-06	2.19e-05	CbGpPWpGaD
